Re-examining Metoclopramide’s Role in Prevention of Postoperative Nausea and/or Vomiting

Amy Masiongale, DNP, CRNA; Jane Garvin, PhD, APRN, FNP-BC; Marguerite Murphy, DNP, RN; Stephen W. Looney, PhD
College of Nursing, Georgia Regents University (soon to be Augusta University), Augusta, GA

INTRODUCTION

• Postoperative nausea and/or vomiting (PONV) continue to be two of the most undesirable and distressing complications following general anesthesia, affecting 20-30% of all surgical patients and up to 70% of patients with multiple known risk factors 1-4
• Clinical guidelines recommend identifying PONV prophylactic interventions based on risk score 1-4
• While the guidelines recommend several antiemetics, metoclopramide was not recommended. 5 However, evidence used to support the guidelines is no longer considered valid. 6-13

METHODS

• Data from 2,166 participants in a 12-center, prospective, observational, cohort of adult ambulatory surgical patients who underwent general anesthesia 3
• PONV risk scores were calculated with Apfel’s risk score 2
• Intraoperative antiemetic treatments were defined as:
  1) metoclopramide 10 mg IV
  2) metoclopramide 10 mg IV + dexamethasone 8 mg IV
  3) metoclopramide 10 mg IV + ondansetron 4 mg IV
  4) metoclopramide 10 mg IV + dexamethasone 8 mg IV + ondansetron 4 mg IV
• PONV ratings at 30, 60, and 120 min after surgery, and at discharge were recoded to dichotomous variables to determine PONV
• Exact methods based on the binomial distribution were used to compare the observed incidence of PONV in the postanesthesia care unit (PACU) to the expected incidence based on PONV risk score

RESULTS

Table 1. Patient Demographics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>49.7 (15.4)</td>
</tr>
<tr>
<td>BMI</td>
<td>28.3 (6.9)</td>
</tr>
</tbody>
</table>

Table 2. Observed Incidence of PONV by PONV Risk Score

<table>
<thead>
<tr>
<th>Expected Incidence of PONV by Risk Score</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Met Only</td>
<td>3/12 (25%)</td>
<td>0/1 (0%)</td>
<td>0/4 (0%)</td>
<td>3/6 (50%)</td>
<td>0/1 (0%)</td>
</tr>
<tr>
<td>Met/Dex</td>
<td>0/1 (0%)</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Met/Odn</td>
<td>10/56 (18%)</td>
<td>0/5 (0%)</td>
<td>1/12 (8%)</td>
<td>4/25 (16%)</td>
<td>5/14 (36%)</td>
</tr>
<tr>
<td>Met/Odn/Dex</td>
<td>9/34 (27%)</td>
<td>0/1 (0%)</td>
<td>0/4 (0%)</td>
<td>3/12 (25%)</td>
<td>6/17 (35%)</td>
</tr>
</tbody>
</table>

Note: Beneficial effect: * = small; ++ = medium; +++ = large;  * = p < 0.05; ** = p < 0.001

CONCLUSIONS

• Incidence of PONV was less than expected based on PONV risk scores across all levels of risk among participants who received one of the metoclopramide antiemetic treatments
• Recommend further studies of metoclopramide’s effectiveness in randomized control trials as a single agent and in combination with other antiemetics based on PONV risk scores
• Recommend clinical guidelines be revised to include metoclopramide as an option
• Metoclopramide is a viable choice as a single agent for patients at low-risk for PONV
• Metoclopramide is a viable choice in combination with dexamethasone and/or ondansetron for patients at moderate to high risk for PONV

ACKNOWLEDGEMENTS

The investigators thank Dr. Christian Apfel and his study team for collecting and sharing the data, Oliver C. Radke for maintaining the original data, Dr. Vallerie Hooper and Dr. Jan Odom-Forren for their assistance in interpreting the data, and Sun Chu for assistance in validating the coding.

Author contact information: amasiongale@gru.edu

REFERENCES

5. Gan TJ. Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist-based pharmacotherapy. CNS Drugs. 2007;21(10):813-833.